Sequencing therapies in oncogene-driven non-small-cell lung cancer: How to get the best mileage?

Vineeth Sukrithan; Rose Snyder; Haiying Cheng; Balázs Halmos

doi:10.2217/fon-2019-0103

Sequencing therapies in oncogene-driven non-small-cell lung cancer: How to get the best mileage?

Vineeth Sukrithan, Rose Snyder, Haiying Cheng, Balázs Halmos

Oncology

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	2899-2904
Number of pages	6
Journal	Future Oncology
Volume	15
Issue number	25
DOIs	https://doi.org/10.2217/fon-2019-0103
State	Published - 2019

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2019-0103

Cite this

@article{4df68016ae5f4ffc8bee8304a6677f8d,

title = "Sequencing therapies in oncogene-driven non-small-cell lung cancer: How to get the best mileage?",

author = "Vineeth Sukrithan and Rose Snyder and Haiying Cheng and Bal{\'a}zs Halmos",

note = "Funding Information: B Halmos reports grants and personal fees from AstraZeneca, grants from Mirati, grants and personal fees from Boehringer In-gelheim, personal fees from Genentech, grants and personal fees from Eli Lilly, grants and personal fees from Merck, grants and personal fees from BMS, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Spectrum, personal fees from Ignyta, grants and personal fees from Takeda, personal fees from Foundation Medicine, grants and personal fees from Guardant Health, outside the submitted work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

doi = "10.2217/fon-2019-0103",

language = "English (US)",

volume = "15",

pages = "2899--2904",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "25",

}

TY - JOUR

T1 - Sequencing therapies in oncogene-driven non-small-cell lung cancer

T2 - How to get the best mileage?

AU - Sukrithan, Vineeth

AU - Snyder, Rose

AU - Cheng, Haiying

AU - Halmos, Balázs

N1 - Funding Information: B Halmos reports grants and personal fees from AstraZeneca, grants from Mirati, grants and personal fees from Boehringer In-gelheim, personal fees from Genentech, grants and personal fees from Eli Lilly, grants and personal fees from Merck, grants and personal fees from BMS, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Spectrum, personal fees from Ignyta, grants and personal fees from Takeda, personal fees from Foundation Medicine, grants and personal fees from Guardant Health, outside the submitted work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85071619855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071619855&partnerID=8YFLogxK

U2 - 10.2217/fon-2019-0103

DO - 10.2217/fon-2019-0103

M3 - Review article

C2 - 31424276

AN - SCOPUS:85071619855

SN - 1479-6694

VL - 15

SP - 2899

EP - 2904

JO - Future Oncology

JF - Future Oncology

IS - 25

ER -

Sequencing therapies in oncogene-driven non-small-cell lung cancer: How to get the best mileage?

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this